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Abstract:  Infections caused by drug-resistant pathogens are on the rise. The ongoing 
spread of methicillin-resistant Staphylococcus aureus (MRSA) strains exemplifies the urgent 
need for new antibiotics. The marine natural product, marinopyrrole A, was previously 
shown to have potent antibiotic activity against Gram-positive pathogens, including 
MRSA. However, its minimum inhibitory concentration (MIC) against MRSA was increased 
by >500 fold in the presence of 20% human serum, thus greatly limiting therapeutic 
potential. Here we report our discovery of a novel derivative of marinopyrrole A, 
designated 1a, featuring a 2–4 fold improved MIC against MRSA and significantly less 
susceptibility to serum inhibition. Importantly, compound 1a displayed rapid and 
concentration-dependent killing of MRSA. Compared to the natural product counterpart, 
compound 1a provides an important natural product based scaffold for further Structure 
Activity Relationship (SAR) and optimization. 
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Marinopyrroles were first reported to show antibiotic activity against methicillin-resistant 
Staphylococcus aureus (MRSA) several years ago [1]. Structural elucidation of the isolated 
marinopyrroles from an obligate marine Streptomyces (strain CNQ-418, collected from the sea floor 
near La Jolla, CA) by 2D NMR and X-ray crystallography revealed an unprecedented structure class. 
The densely halogenated 1,3-bipyrroles represented by marinopyrrole A (±)-1 exist as enantiopure  
M-(−)-atropisomer, (−)-1, at ambient temperature (Chart 1). The enantiomer (+)-1 was obtained after a 
chiral separation of synthetic (±)-1 using chiral HPLC [2]. Due to their novel class of molecular 
structures and promising biological properties, the marinopyrroles have attracted considerable 
attention. In the last few years since the discovery of this uncommon bispyrrole structure of marine 
natural products, several synthetic and semi-synthetic efforts have successfully yielded a few series of 
novel marinopyrrole derivatives [2–6]. 
Chart 1. Chemical structures of marinopyrrole A. 
 
The global crisis of antibiotic resistance has spread rapidly over the last several decades. MRSA 
infections have reached epidemic proportions in many countries [7] and represent the most common 
cause of skin and soft tissue infections in the United States [8]. Both hospital-associated and 
community-associated MRSA can exhibit broader resistance to multiple classes of antibiotics [7,9–11]. 
Hospital-associated MRSA (HA-MRSA) infections are common among healthcare facilities and are 
resistant to many antibiotics. However, community-associated MRSA (CA-MRSA) strains are highly 
virulent and infect even healthy individuals; the incidence of these infections has skyrocketed in the 
last decade. The relative abandonment of antibiotic discovery and development by the pharmaceutical 
industry has created a vacuum in the introduction of new antibiotics to treat these increasingly 
problematic infections. Except for the addition of the oxazolidinone linezolid [12] in 2000, the 
lipopeptide daptomycin [13] in 2003, and FDA’s most recent approval of ceftaroline (Teflaro) [14] as 
an injectable antibiotic to treat adults with community acquired bacterial pneumonia (CABP) and acute 
bacterial skin and skin structure infections (ABSSSI) including MRSA, a very limited number of new 
antibiotics have been discovered over the last half a century, with only two new classes of anti-MRSA 
drugs having been approved in the last 40 years. Clearly, novel agents for the treatment of MRSA 
infections are urgently needed [15]. 
Recently, evaluation of the pharmacological properties has revealed that marinopyrrole A has   
potent concentration-dependent antibacterial activity against clinically-relevant hospital- and 
community-acquired MRSA strains, a prolonged post-antibiotic effect superior to the first-line current Mar. Drugs 2012, 10 955 
 
 
agents vancomycin and linezolid, and a favorable resistance profile [16]. Although marinopyrrole A 
(±)-1, (−)-1 and (+)-1 showed potent antibiotic activity [2] with limited toxicity to mammalian cell 
lines at >20× MIC, their antibiotic activity against MRSA were inhibited by 20% human serum [16]. 
Previous studies of synthetic or semi-synthetic marinopyrrole derivatives to date have yielded no new 
analogs that retained antibacterial activity in the presence of human serum [16], constituting a major 
challenge for therapeutic development. Here, we report our design and synthesis of novel 
marinopyrrole derivatives with excellent antibiotic activity against MRSA but only limited   
serum inactivation. 
2. Results and Discussion 
2.1. Synthesis and Structure Activity Relationships of Asymmetrical Marinopyrrole Derivatives 
Two years ago, we reported the first total synthesis of marinopyrrole A along with “symmetrical” 
derivatives, (±)-1 and 12 analogs, which bear the same substituents with the same substitution pattern 
on both phenyl ring A and B attached to the carbonyl groups (Chart 1) [6]. In addition to those 
symmetrical marinopyrrole derivatives, we envisage that the “asymmetrical” marinopyrrole derivatives 
shown in Scheme 1 should have different biological activity than their symmetrical counterparts.   
In particular, the molecules with diverse functional groups decorated on this unique 1,3-bipyrrole 
system may adopt specific conformations due to the restricted free rotation of the chiral axis. To this 
end, a series of novel asymmetrical marinopyrrole derivatives were designed and synthesized. 
Scheme 1. Synthesis of Novel Asymmetrical Marinopyrrole Derivatives 
a. 
 
a Conditions: (i) PPTS, 1,4-dioxane, reflux, 53%; (ii) 6.0 eq. 5, THF, −78 °C, 85%; (iii) SOCl2, 
benzene, reflux; (iv) 1.2 eq. 8, 1.3 eq. AlCl3, DCM, 0–25 °C, 70%; (v) 1.0 eq. 9a, 4.1 eq. SO2Cl2, 
DCM, 0 °C, 85%; (vi) 1.0 eq. 10a, 4.0 eq. BBr3, DCM, −78 °C, 96%.  
Chemistries to access both symmetrical and asymmetrical marinopyrrole derivatives were   
reported previously [2,6]. Briefly, 2-ethoxycarbonyl-3-aminopyrrole 2 was obtained using a   
published procedure [17]. A PPTS-promoted Clauson–Kaas reaction [2,18] between 2 and   Mar. Drugs 2012, 10 956 
 
 
2,5-dimethoxy-tetrahydrafuran 3 in dioxane under reflux gave rise to bispyrrole 4 in 53% yields. The 
mono-addition of lithiated anisole 5 to bispyrrole ester 4 in THF at −78 °C furnished mono acylated 
bispyrrole 6 in 85% yield [2]. Friedel–Crafts arylation of 6 with the acid chlorides 8, generated in situ 
from the corresponding carboxylic acids 7 with thionyl chloride, afforded a series of marinopyrrole 
precursor 9a–9c. A novel series of asymmetrical marinopyrrole derivatives 10a–10c were obtained by 
tetrachlorination of the corresponding 9a–9c using 4.1 equivalents of sulfuryl chloride (SO2Cl2)  
in DCM at 0 °C. Demethylation of 10a–10c using BBr3 in DCM furnished 1a–1c in >90% yield 
(Scheme 1) [2,6]. 
The anti-MRSA activity of the novel asymmetrical marinopyrroles shown in Scheme 1 was 
evaluated against a USA300 strain of community-associated MRSA. One of the derivatives,   
(4-chloro-2-hydroxyphenyl) (4,4′,5,5′-tetrachloro-2′-(2-hydroxybenzoyl)-1′H-1,3′-bipyrrol-2-yl)methanone 
(1a), exhibited potent antibacterial activity. The 2–4 fold improvement in antibacterial activity from 
the parent compound 1 was observed for this novel marinopyrrole derivative 1a as shown in Table 1. 
The corresponding dimethoxy-congener, (4-chloro-2-methoxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-methoxy 
benzoyl)-1′H-1,3′-bipyrrol-2-yl)methanone, 10a, was found to be inactive against MRSA at >200 μM. 
This observation is consistent with the result reported previously for compound 1 and its 
corresponding methoxy analog [2] as compound 1a showed >1000 fold more potency than 10a. This 
observed SAR was also supported by the current results from compounds 1b and 1c. Compound 1b, 
with a chloro-substituent ortho to the hydroxyl group, was >128-fold more potent than 10a, whereas 
derivative 1c with chloro-substituent para to the hydroxyl group showed >64-fold more anti-MRSA 
activity than 10b. Compound 1a has the chloro-substituent meta to the hydroxyl group exhibiting  
8–16-fold and 4–8-fold more anti-MRSA activity than 1c and 1b, respectively. The fact that the free 
hydroxyl groups are essential for the antibacterial activity suggested that the binding sites may contain 
both hydrogen bond donors and hydrogen bond receptors. Although the internal hydrogen bonding 
between the phenyl hydroxyl and adjacent carbonyl group was observed in an X-ray structure of   
(−)-1 [1] and compounds 1a–1c may behave similarly, this interaction can be weakened or interrupted 
if appropriate amino acid residues, such as Arg, His, Asn, Asp, Glu or Gln, are close by for 
interactions. Although thorough investigation is required to understand the observed structure activity 
relationships generated by compounds 1a–1c, their physicochemical properties on the OR5 group in B 
ring due to the difference in pKa values of their hydroxyl groups might, at least in part, play an 
essential role in addition to the different substitution pattern. 
Table 1. Minimum inhibitory concentration (MIC) of Marinopyrrole Derivatives against 
methicillin-resistant Staphylococcus aureus (MRSA). 
Compound  THB  THB + 20% Serum 
1 (parent)  0.74 94–188 
10a  >200 >200 
1a  0.19–0.39 12.5–25 
1b  1.56 >200 
1c  3.13 >200 
MIC in μM in Todd-Hewitt broth (THB) in the absence or presence of 20% human serum. All data were 
generated from experiments repeated four times. Mar. Drugs 2012, 10 957 
 
 
Most significantly, not only did compound 1a show increased antibacterial activity compared to the 
parent compound, marinopyrrole A (1), but its activity was also less inhibited upon the addition of 
20% human serum (MIC 12.5–25 µM vs. 100–200 µM). In comparison to contemporary MRSA 
agents, compound 1a is more potent than vancomycin and linezolid against USA300 MRSA strain 
TCH1516 [16]. 
2.2. In Vitro Time-Kill of Marinopyrrole Derivative 1a 
In vitro time-kill studies were performed to characterize killing kinetics of derivative 1a at 20×, 10× 
and 1× MIC and to compare them with that of the parent natural product marinopyrrole A   
(−)-1 [16]. Derivative 1a displayed strong concentration-dependent MRSA killing that was much more 
rapid than vancomycin or linezolid and was similar in profile to the parent compound [16].   
The potency of derivative 1a was especially evident at 20× the MIC (3.8 μM), yielding greater than a 
4-log kill of MRSA at 4 h. This feature parallels the effects seen with the natural product parent 
compound (−)-1. 
Compound (−)-1 was also shown to have a favorable therapeutic index at 24 h in treated 
mammalian cells [16]. The natural product marinopyrrole A had a low propensity for toxicity at 
concentrations below 20× MIC. Upon closer examination, derivative 1a displays more potent MRSA 
killing effects. For example, the tested concentration of 1a (MIC 0.39 μM) was half of the concentration 
of the parent natural product tested in time-kill analyses (MIC 0.75 μM or 0.375 μg/mL) [16]. 
Secondly, at 3.9 μM (10× MIC) and 6 h incubation, 1a causes 3-log decrease in bacterial survival 
(Figure 1). This improved upon the kinetics of the natural product, (−)-1, which generated only a  
two-log decrease in bacterial survival [16]. Furthermore, the actual tested compound concentration of 
(−)-1 was 7.5 μM, a fold higher than that of derivative 1a (3.9 μM) (Figure 1). Similar to (−)-1, this 
activity is much more rapid than vancomycin or linezolid [16]. In summary, we have discovered a 
novel natural product based derivative that retains the favorable and potent concentration-dependent 
bacterial killing characteristic of the natural product but at a lower concentration. 
Figure 1.  In vitro Time-kill Analysis for Marinopyrrole Derivative (1a) against the 
USA300 Community-associated MRSA Strain TCH1516. MRSA was subjected to 
increasing concentrations of 1× (0.39 μM), 10× (3.9 μM) and 20× (7.8 μM) the MIC   
of derivative 1a or vehicle control (none). Derivative 1a showed potent   
concentration-dependent in vitro bactericidal kinetics against MRSA at 10× (3.9 μM) and 
20× (7.8 μM) MIC, along with bacteriostatic activity at 1× MIC (0.39 μM). 
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3. Experimental Section  
3.1. Synthesis of Compounds 4–10c 
All chemicals and solvents were purchased from commercial suppliers and used without further 
purification. Preparative flash column chromatography was performed on silica gel 60, 0.040–0.063 mm 
(EMD Chemicals). 
1H NMR (400 MHz) spectra were recorded on a Varian AS400 with a 60-place 
automated sample changer. High resolution ESI-MS spectra were recorded on an Agilent ESI-TOF 
LC-MS 6200 system. Preparative HPLC was performed on a Gilson HPLC system with UV detectors 
and Gilson 215 liquid handler for auto injection and fraction collections (customized by HT Labs,  
San Diego, CA, USA). Analytical HPLC was performed on an Agilent 1100 series with diode array 
detectors and auto samplers. The specifications of HPLC analysis are as follows: flow rate, 1 mL/min; 
column, Intertsil, 2.5 μm, 4.6 × 150 mm; wavelength, 254 and 280 nm; mobile phase, A: H2O with 
0.1% HCO2H, B: MeOH, gradient of 50–95% B in 25 min. All tested compounds possessed a purity of 
not less than 95%. 
Ethyl 1′H-1,3′-bipyrrole-2′-carboxylate (4). To a stirred solution of 2,5-dimethoxy-tetrahydrofuran 3 
(1.6 mL, 12.4 mmol, 1.3 equiv) and PPTS (3.2 g, 12.4 mmol, 1.3 equiv) in 1,4-dioxane (20 mL) at  
50 °C, a solution of aminopyrrole 2 (1.47 g, 9.55 mmol, 1.0 eq.) in 1,4-dioxane (6 mL) was added 
slowly. The resulting mixture was brought to reflux and stirred for 1 h. The reaction mixture was then 
concentrated, dissolved in EtOAc (50 mL) and dried over anhydrous MgSO4. The crude product was 
purified by flash column chromatography (10% EtOAc in hexane) to give 4 as a yellow solid (1.036 g, 
53% yield). 
1H NMR (400 MHz, CDCl3) δ 8.99 (s, 1H), 7.04–7.01 (m, 2H), 6.89 (t, J = 3.1 Hz, 1H), 
6.29 (t, J = 2.9 Hz, 1H), 6.27–6.24 (m, 2H), 4.28 (q, J = 7.1 Hz, 2H), 1.29 (t, J = 7.1 Hz, 3H). 
1′H-1,3′-Bipyrrol-2′-yl(2-methoxyphenyl)methanone (6). To a solution of 2-bromoanisole   
(1.39 g, 7.43 mmol, 5.63 equiv) in anhydrous THF (5 mL) at −78 °C, a 2.5M solution of BuLi in 
hexane (3 mL, 7.50 mmol, 5.68 eq.) was added dropwise, the resulting mixture was stirred for 1 h. at 
−78 °C to generate the lithiated anisole. In an oven-dried flask, compound 4 (270 mg, 1.32 mmol, 1 eq.) 
was dissolved in THF (5 mL) and cooled to −78 °C, the lithiated anisole 5 was transferred into the 
solution containing 4 dropwise via syringe, and the resulting mixture was stirred for 1 h. at −78 °C. To 
the reaction mixture, an aqueous solution of NH4Cl (5 mL) was added, the mixture was extracted with 
EtOAc, dried over anhydrous Na2SO4. The crude product was purified by flash column chromatography 
(10% EtOAc in hexane) to give 6 as a light brown solid (0.30 g, 85% yield). 
1H NMR (400 MHz, 
CDCl3) δ 9.35 (s, 1H), 7.28–7.22 (m, 1H), 7.20 (dd, J = 7.5, 1.7 Hz, 1H), 7.02 (t, J = 3.0 Hz, 1H),  
6.80 (td, J = 7.5, 0.9 Hz, 1H), 6.68 (d, J = 8.4 Hz, 1H), 6.48–6.43 (m, 2H), 6.27 (t, J = 2.8 Hz, 1H), 
5.88 (m, 2H), 3.63 (s, 3H). 
(2-(4-Chloro-2-methoxybenzoyl)-1′H-1,3′-bipyrrol-2′-yl)(2-methoxyphenyl)methanone (9a). Into a 
solution of 4-chloro-2-methoxybenzoic acid (125 mg, 0.67 mmol, 1.2 eq.) in benzene (1.5 mL), SOCl2 
(1.5 mL) was added at room temperature and the resulting solution was refluxed for 2 h. The reaction 
mixture was concentrated under vacuum to generate 4-chloro-2-methoxybenzoyl chloride 8a which 
was used directly in the next step without purification. A solution of 8a in CH2Cl2 (DCM) (2 mL) was 
added to a slurry of AlCl3 (96 mg, 1.3 eq.) in DCM (2.5 mL) at 0 °C and then a solution of 6 (150 mg, Mar. Drugs 2012, 10 959 
 
 
0.56 mmol, 1.0 equiv) in DCM (1.5 mL) was added dropwise. The resulting solution was allowed to 
warm to room temperature and stirred overnight. A saturated solution of NaHCO3 (10 mL) and DCM 
(10 mL) was then added and the resulting mixture was stirred for 1 h, and then filtered though Celite
®. 
The mixture was extracted with DCM (2 × 10 mL), the organic layer was dried over anhydrous 
Na2SO4, and purified by flash column chromatography (hexanes:EtOAc) to afford 172 mg of 9a as a 
white solid, 70% yield. 
1H NMR (400 MHz, CDCl3) δ 9.83 (s, 1H), 7.22–7.14 (m, 2H), 7.12 (d, J = 7.8 Hz, 
1H), 7.04 (t, J = 3.0 Hz, 1H), 6.95–6.88 (m, 2H), 6.73–6.63 (m, 3H), 6.31 (dd, J = 4.0, 1.7 Hz, 1H), 
6.27 (t, J = 2.8 Hz, 1H), 5.83 (dd, J = 4.0, 2.6 Hz, 1H), 3.77 (s, 3H), 3.69 (s, 3H). 
(2-(5-Chloro-2-methoxybenzoyl)-1′H-1,3′-bipyrrol-2′-yl)(2-methoxyphenyl)methanone (9b).  
5-Chloro-2-methoxybenzoyl chloride (8b) was generated in situ from the corresponding acid using the 
same method as 8a. Compound 9b (88 mg, 67% yield) was obtained using the same method as 9a 
described above. 
1H NMR (400 MHz, CDCL3) δ 9.78 (s, 1H), 7.31 (dd, J = 8.8, 2.7 Hz, 1H), 7.25–7.15 
(m, 2H), 7.06 (dd, J = 4.3, 1.7 Hz, 2H), 6.85 (d, J = 8.9 Hz, 1H), 6.77–6.66 (m, 3H), 6.32 (dd, J = 4.0, 
1.7 Hz, 1H), 6.30 (t, J = 2.8 Hz, 1H), 5.87 (dd, J = 4.0, 2.6 Hz, 1H), 3.75 (s, 3H), 3.69 (s, 3H). 
(2-(3-Chloro-2-methoxybenzoyl)-1′H-1,3′-bipyrrol-2′-yl)(2-methoxyphenyl)methanone (9c).  
3-Chloro-2-methoxybenzoyl chloride (8c) was generated in situ from the corresponding acid using the 
same method as 8a. Compound 9c (90 mg, 68% yield) was obtained using the same method as 9a 
described above. 
1H NMR (400 MHz, CDCL3) δ 9.81 (s, 1H), 7.52 (dd, J = 7.8, 1.6 Hz, 1H), 7.39 (dd, 
J = 8.0, 1.6 Hz, 1H), 7.24–7.19 (m, 1H), 7.10 (dt, J = 5.7, 2.2 Hz, 2H), 6.87 (dd, J = 2.6, 1.6 Hz, 1H), 
6.79 (d, J = 7.9 Hz, 1H), 6.66–6.59 (m, 3H), 6.31 (t, J = 2.8 Hz, 1H), 6.05 (dd, J = 4.1, 2.6 Hz, 1H), 
3.57 (s, 3H), 3.52 (s, 3H). 
(4-Chloro-2-methoxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-methoxybenzoyl)-1′H-[1,3′-bipyrrole]-2-yl) 
methanone (10a). To a solution of compound 9a (82 mg, 0.19 mmol, 1 eq.) in DCM (5 mL) at 0 °C, 
SO2Cl2 (64 μL, 0.78 mmol, 4.1 equiv) was added dropwise, and the solution was allowed to stir at 0 °C 
for 1 h. Saturated aqueous NaHCO3 solution (2 mL) was added and the resulting mixture was extracted 
with DCM (3 × 4 mL). The combined organic layers were dried with anhydrous MgSO4, filtered, and 
concentrated. The residue was purified by flash column chromatography (silica gel, hexane:EtOAc 
4:1) to afford 10a (92 mg, 85% yield) as an off-white solid. 
1H NMR (400 MHz, CDCl3) δ 10.38  
(s, 1H), 7.25–7.21 (m, 2H), 7.13 (d, J = 7.9 Hz, 1H), 6.96–6.94 (m, 2H), 6.76 (d, J = 8.3 Hz, 1H),  
6.68 (t, J = 7.8 Hz, 1H), 6.31 (s, 1H), 3.80 (s, 3H), 3.72 (s, 3H); HRMS (ESI-TOF) [M + H]
+ calcd for 
C24H16Cl5N2O4 570.9547, found 570.9537; HPLC purity, 95.2%. 
(5-Chloro-2-methoxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-methoxybenzoyl)-1′H-1,3′-bipyrrol-2-yl) 
methanone (10b). The same procedure described for 10a was used to synthesize 10b (87 mg, 80% 
yield). 
1H NMR (400 MHz, CDCL3)  δ 10.28 (s, 1H), 7.36 (dd, J = 8.9, 2.7 Hz, 1H), 7.31–7.27   
(m, 1H), 7.19 (dd, J = 7.5, 1.7 Hz, 1H), 7.07 (d, J = 2.6 Hz, 1H), 6.88 (d, J = 8.9 Hz, 1H), 6.79  
(d, J = 8.4 Hz, 1H), 6.73 (td, J = 7.5, 0.8 Hz, 1H), 6.33 (s, 1H), 3.78 (s, 3H), 3.73 (s, 3H). 
(3-Chloro-2-methoxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-methoxybenzoyl)-1′H-1,3′-bipyrrol-2-yl) 
methanone (10c). The same procedure described for 10a was used to synthesize 10c (80 mg, 74%).  
1H NMR (400 MHz, CDCL3) δ 10.30 (s, 1H), 7.57 (dd, J = 7.9, 1.5 Hz, 1H), 7.37–7.27 (m, 2H), 7.11 Mar. Drugs 2012, 10 960 
 
 
(dd, J = 7.5, 1.7 Hz, 1H), 6.85 (t, J = 7.9 Hz, 1H), 6.76 (d, J = 8.4 Hz, 1H), 6.67 (t, J = 7.5 Hz, 1H), 
6.57 (s, 1H), 3.83 (s, 3H), 3.73 (s, 3H). 
3.2. Synthesis of Compounds 1a–1c 
(4-Chloro-2-hydroxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-hydroxybenzoyl)-1′H-1,3′-bipyrrol-2-yl) 
methanone (1a). To a solution of 10a (33 mg, 0.058 mmol) in anhydrous DCM (1 mL) was slowly 
added 1.0 M solution of BBr3 in DCM (23 μL, 0.23 mmol, 4 eq.) via a syringe under N2 at −78 °C. 
After being stirred for 0.5 h, the mixture was quenched by addition of MeOH (0.5 mL) and extracted 
with DCM (3 × 10 mL). The combined organic layers were dried over anhydrous MgSO4, filtered and 
concentrated in vacuum. The residue was purified by column chromatography (silica gel, hexanes:12% 
EtOAc) to give 1a (30 mg, 96% yield) as a yellow solid. 
1H NMR (400 MHz, CDCl3) δ 11.34 (s, 1H), 
10.39 (s, 1H), 9.77 (s, 1H), 7.47 (d, J = 8.6 Hz, 1H), 7.43 (dd, J = 8.0, 1.7 Hz, 1H), 7.36 (ddd, J = 8.8, 
7.4, 1.6 Hz, 1H), 7.04 (d, J = 2.0 Hz, 1H), 6.95–6.90 (m, 1H), 6.87 (dd, J = 8.6, 2.0 Hz, 1H), 6.68  
(s, 1H), 6.53 (ddd, J = 8.0, 7.3, 1.1 Hz, 1H); HRMS (ESI-TOF) [M + H]
+ calcd for C22H12Cl5N2O4 
542.9234, found 542.9237; HPLC purity 96.6%. 
(5-Chloro-2-hydroxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-hydroxybenzoyl)-1′H-1,3′-bipyrrol-2-yl) 
methanone (1b). The same procedure as 1a was followed to obtain 1b (28 mg, 90%) from 10b  
(31 mg, 0.055 mmol). 
1H NMR (400 MHz, CDCL3) δ 11.10 (s, 1H), 10.33 (s, 1H), 9.89 (s, 1H), 8.06 
(dd, J = 7.9, 1.8 Hz, 1H), 7.95 (d, J = 2.4 Hz, 1H), 7.83 (d, J = 8.3 Hz, 1H), 7.71–7.64 (m, 1H),  
7.49–7.41 (m, 2H), 6.97 (dd, J = 8.9, 2.1 Hz, 1H), 6.87 (s, 1H); HRMS (ESI-TOF) [M + Na]
+ calcd for 
C22H11Cl5N2O4Na 564.9054, found 564.9055; HPLC purity, 95.0%. 
(3-Chloro-2-hydroxyphenyl)(4,4′,5,5′-tetrachloro-2′-(2-hydroxybenzoyl)-1′H-1,3′-bipyrrol-2-yl) 
methanone (1c). The same procedure as 1a was followed to obtain 1c (26 mg, 91%) from 10c  
(29 mg, 0.05mmol). 
1H NMR (400 MHz, CDCL3) δ 11.74 (s, 1H), 10.48 (s, 1H), 9.93 (s, 1H), 8.06  
(d, J = 7.9 Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.82 (d, J = 8.2 Hz, 1H), 7.67 (t, J = 7.8 Hz, 1H), 7.61  
(d, J = 7.9 Hz, 1H), 7.45 (t, J = 7.6 Hz, 1H), 6.96 (t, J = 7.9 Hz, 1H), 6.83 (s, 1H); HRMS (ESI-TOF)  
[M + Na]
+ calcd for C22H11Cl5N2O4Na 564.9054, found 564.9058; HPLC purity, 97.4%. 
3.3. In Vitro Antibacterial Assays 
TCH1516, a USA300 strain of community-associated MRSA, was obtained from the American 
Type Culture Collection and used for biological assays. MICs were determined by broth microdilution 
according to Clinical and Laboratory Standards Institute guidelines except that Todd-Hewitt broth 
(THB) was used in place of Mueller-Hinton broth. Assays were done in 96-well tissue-culture treated 
plates. Vancomycin served as a control antibiotic. MIC assays in 20% human serum were assessed by 
bacterial metabolic activity in resazurin as described [16]. 
3.4. In Vitro Time-Kill Analysis 
The bactericidal activity of derivative 1a against the CA-MRSA isolate TCH1516 were assessed by 
time-kill analysis essentially as described previously [16,19–21]. Briefly, MRSA was grown overnight 
in Todd-Hewitt Broth (THB) at 37 °C with shaking. Following overnight growth, MRSA was Mar. Drugs 2012, 10 961 
 
 
inoculated in fresh media for growth to mid-logarithmic phase. At the start of the time-kill assay, 
bacteria (starting inoculum ~5 × 10
5 cfu/mL) were added to duplicate 5 mL polystyrene round-bottom 
tubes (Falcon, Bedford, MA, USA) containing 20×, 10×, 1×, none of the MIC of derivative 1a 
(0.39 μM) or an equivalent amount of DMSO vehicle control (Figure 1, none). These cultures were 
incubated in a shaking 37 °C incubator for 24 h. To determine the rate of antibiotic killing, small 
aliquots were removed from tubes at 0, 3, 6 and 24 h and serially diluted for cfu enumeration on THA 
plates. The limit of detection for the time-kill assay was 1.6 (log10 cfu/mL). 
4. Conclusions  
In summary, we designed and synthesized a novel series of asymmetrical derivatives of marine 
natural product, marinopyrrole A, and discovered that a novel derivative, 1a (MIC = 0.19–0.39 μM), 
exhibits significantly greater activity than linezolid and vancomycin against MRSA. Moreover, in vitro 
time-kill kinetics of 1a demonstrated potent concentration-dependent killing. These qualities were 
similar to those displayed by the parent natural product in time-kill studies, but 1a was   
2–4-fold more potent at lower compound concentrations. One of the main drawbacks of the natural 
product has been its significant inhibition in the presence of human serum. For example, the antibiotic 
activity of (−)-1 was inactivated (MIC increased 256–522×) in the presence of serum [16]. Here, 1a 
again exhibits an advantage, with only 32–64 fold increase in MIC in 20% human serum (Table 1). 
Further derivatization and SAR optimization will aim to engineer out the propensity for serum 
inhibition. Design and synthesis of both symmetrical and asymmetrical marinopyrrole derivatives are 
actively ongoing. The optimization of their structure and activity for use as potential antibiotic agents 
against MRSA will be reported in due course. 
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